Is ABL Biotechnologies Ltd (526955) a good quality company?

Data is not available for this company.

What is ABL Biotechnologies Ltd (526955) share price return in the past 10 years?

Data is not available for this company

What is the share price of ABL Biotechnologies Ltd (526955)?

Company share prices are keep on changing according to the market conditions. The current trading price of ABL Biotechnologies Ltd (526955) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of ABL Biotechnologies?

The latest standalone P/E ratio of ABL Biotechnologies as of 01-Jan-1970 is 0.00.

What is the P/B ratio of ABL Biotechnologies Ltd (526955)?

The latest standalone P/B ratio of ABL Biotechnologies Ltd (526955) as of 01-Jan-1970 is 0.05.

What is the 52-week high and low of ABL Biotechnologies Ltd (526955)?

The 52-week high of ABL Biotechnologies Ltd (526955) is Rs. 0.81 and the 52-week low is Rs. 0.75.

ABL Biotechnologies Ltd (526955) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: ABL Biotechnologies Ltd (526955)
Brand: ABL Biotechnologies

ABL Biotechnologies Ltd (526955) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

ABL Biotechnologies Ltd (526955)

BSE: 526955 NSE:

Key Metrics

Market Cap

₹1 Cr.

P/E Ratio

0.00

Price to Book (P/B)

0.05

Price to Sales (P/S)

0.00

EV/EBITDA

-677.96

Return on Capital Employed (ROCE)

-0.56%

Current Price

₹0

Return on Equity (ROE)

-1.24%

Return on Assets (ROA)

-0.40%

Operating Profit Margin

Net Profit Margin

-INF%

Gross Profit Margin

Book Value per Share

₹17.3

Sales Growth (YoY)

-100%

Sales Growth (3 Years)

-100%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

NAN%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹1 / 1

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

0.60%

Pledged shares (%)
of Promoter's holding (%)

0.00%

DeciZen - make an informed investing decision on ABL Biotechnologies

Based on:

Data

M-Cap below 100cr DeciZen not available

ABL Biotechnologies stock performance

Key Ratios

Is an attractive stock to invest in?

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
ROCE % ⓘ	-3.5%	3.3%	21.8%	32.3%	22.4%	15.1%	0.5%	-48%	-1.9%	-0.6%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.2	2.6	5.8	7	9.3	16.9	8.2	2.2	0	0	0
Sales YoY Gr.	-	1,400%	127.5%	20.9%	32.2%	81.9%	-51.7%	-72.8%	-98.2%	-100%	-
Adj EPS ⓘ	-0.4	0.2	1	4.1	5.3	4.4	-1.2	-25.2	-0.7	-0.2	-0.2
YoY Gr.	-	NA	325%	302%	28.3%	-16.9%	-126.8%	NA	NA	NA	-
BVPS (₹) ⓘ	5.6	5.5	6.2	9	16.6	20.4	43.3	18.4	17.8	17.6	17.3
Adj Net Profit ⓘ	-0.1	0.1	0.4	1.7	2.2	1.8	-1	-20.6	-0.6	-0.2	-0
Cash Flow from Ops. ⓘ	0	0.6	0.6	-3.6	1.8	-1.7	0.8	-9.6	-0.5	-0.1	-
Debt/CF from Ops. ⓘ	78.5	1.8	2.8	-1.4	5.7	-8.6	21.3	-1.7	-36.2	-148.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	-100%	-100%	-100%
Adj EPS ⓘ	NA	-153%	NA	NA
BVPSⓘ	13.6%	1.2%	-25.9%	-0.9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
Return on Equity % ⓘ	-5.2	3.7	13.7	40	24.6	14.3	-3.6	-69.3	-3.2	-1	-0.9
Op. Profit Mgn % ⓘ	-114	7.7	11.4	17.7	18.6	19.2	4.9	-899.2	-1266	0	NAN
Net Profit Mgn % ⓘ	-83.6	3.9	7.2	24	23.3	10.6	-11.7	-927.8	-1425	0	-INF
Debt to Equity ⓘ	0.6	0.5	0.6	1.4	1.5	1.7	0.5	1.1	1.2	1.2	0.7
Working Cap Days ⓘ	310	68	69	182	264	253	646	1,613	74,662	0	0
Cash Conv. Cycle ⓘ	-179	-79	-71	-51	-39	-19	-34	-21	-9,356	0	0

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-0.2	-0.2
TTM Sales (₹ Cr.)	0	0
BVPS (₹) ⓘ	17.3	17.3
Reserves (₹ Cr.) ⓘ	6	6
P/BV ⓘ	0.05	0.05
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	0.75 / 0.81
All Time Low / High (₹)	0.73 / 222.00
Market Cap (₹ Cr.)	0.7
Equity (₹ Cr.)	8.2
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of ABL Biotechnologies - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Sales	0.17	2.55	5.80	7.01	9.27	16.86	8.15	2.22	0.04	0
Operating Expenses ⓘ +	0.36	2.36	5.14	5.76	7.56	13.68	7.77	22.23	0.57	0.12
Manufacturing Costs	0.06	0.73	1.60	1.64	1.38	1.56	1.96	0.99	0.01	0
Material Costs	0.08	0.88	1.98	2.73	4.56	9.58	3.58	3.40	0.07	0
Employee Cost	0.07	0.22	0.61	0.60	0.73	1.29	1.19	0.78	0.13	0.02
Other Costs ⓘ	0.15	0.53	0.94	0.79	0.89	1.26	1.04	17.05	0.37	0.10
Operating Profit ⓘ	-0.19	0.19	0.66	1.24	1.71	3.18	0.38	-20	-0.53	-0.12
Operating Profit Margin (%)	-114.0%	7.6%	11.4%	17.7%	18.5%	18.9%	4.7%	-899.0%	-1,266.0%	-
Other Income ⓘ +	0.14	0.03	0	1.01	1.57	0.14	0.01	0	0	0.01
Exceptional Items ⓘ	0.02	0	0.28	0	0	0	0	0	0	0
Interest ⓘ	0	0.02	0.15	0.28	0.62	1.16	1.12	0.52	0	0
Depreciation ⓘ	0.09	0.11	0.15	0.17	0.21	0.22	0.23	0.12	0.07	0.07
Profit Before Tax ⓘ	-0.13	0.10	0.65	1.80	2.46	1.95	-0.95	-20.64	-0.60	-0.18
Tax ⓘ	0	0	0.03	0.13	0.31	0.19	0.01	0	0	0
Profit After Tax	-0.13	0.10	0.61	1.68	2.15	1.75	-0.97	-20.64	-0.60	-0.18
PAT Margin (%)	-76.3%	3.8%	10.6%	24.0%	23.2%	10.4%	-11.9%	-927.0%	-1,425.0%	-
Adjusted EPS (₹)	-0.3	0.2	1.5	4.1	5.2	4.3	-1.2	-25.2	-0.7	-0.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Equity and Liabilities
Shareholders Fund +	2.65	2.75	3.36	5.04	10.86	12.62	40.21	19.33	18.74	18.56
Share Capital ⓘ	4.10	4.10	4.10	4.10	4.10	4.10	8.20	8.20	8.20	8.20
Reserves ⓘ	-1.45	-1.35	-0.74	0.94	6.76	8.52	32.01	11.13	10.54	10.36
Debt +	1.26	1.04	1.51	5.17	10.13	14.15	16.59	16.66	16.97	17.10
Long Term Debt	1.26	1.04	1.51	5.17	10.13	14.15	16.59	16.66	12.65	12.79
Short Term Debt	0	0	0	0	0	0	0	0	4.31	4.31
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.29	1.22	1.96	2.72	4.42	7.29	8.38	8.86	9.53	9.43
Others Liabilities ⓘ	0.12	0.30	0.98	1.61	1.98	0.55	0.50	0.74	0	0
Total Liabilities ⓘ	4.32	5.31	7.81	14.54	27.40	34.61	65.69	45.60	45.23	45.10
Fixed Assets
Net Fixed Assets ⓘ +	2.48	2.73	2.79	2.67	7.38	7.59	7.43	35.10	34.86	34.80
Gross Block	3.12	3.48	3.68	3.66	8.56	8.96	8.98	35.98	35.71	35.72
Accumulated Depreciation	0.63	0.74	0.89	0.98	1.18	1.37	1.56	0.88	0.85	0.92
CWIP ⓘ	0	0	0	0	5.92	7.34	7.62	0	0	0
Investments ⓘ	1.30	1.30	2.40	2.40	1.30	1.30	1.30	1.30	1.30	1.31
Inventories	0.05	0.50	1.36	1.63	2.48	2.97	3	0.07	0	0
Trade Receivables	0.03	0.11	0.14	3.06	3.07	7.55	7.16	0.27	0.32	0.32
Cash Equivalents	0.01	0.01	0	0	2.51	0.18	30.03	0.14	0.14	0.14
Others Assets ⓘ	0.45	0.66	1.12	4.77	4.73	7.68	9.15	8.72	8.61	8.53
Total Assets ⓘ	4.32	5.31	7.81	14.54	27.40	34.61	65.69	45.60	45.23	45.10

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Cash Flow From Operating Activity ⓘ +	0.02	0.58	0.55	-3.61	1.79	-1.65	0.78	-9.56	-0.47	-0.11
PBT ⓘ	-0.13	0.10	0.61	1.68	2.15	1.75	-0.97	-20.64	-0.60	-0.18
Adjustment ⓘ	0.07	-0.02	-0.28	0.03	2.42	1.47	1.19	0.64	0.12	0.12
Changes in Working Capital ⓘ	0.08	0.52	0.37	-5.04	-2.78	-4.87	0.55	10.44	0.01	-0.05
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0	-0.37	-1.30	-0.05	-5.28	-1.90	-0.89	-19.88	0.17	-0.02
Capex	-0	-0.37	-0.20	-0.05	-1.17	-0.48	-0.78	-28.69	0.17	-0.01
Net Investments	0	0	-1.10	0	0	0	0	0	0	-0.01
Others ⓘ	0	0	0	0	-4.10	-1.42	-0.12	8.81	0	0
Cash Flow From Financing Activity ⓘ +	-0	-0.22	0.74	3.66	5.99	1.21	29.97	-0.45	0.30	0.14
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	28.70	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	-0.62	-1.16	-1.12	-0.52	-0	-0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	-0.22	0.74	3.66	6.61	2.37	2.39	0.07	0.30	0.14
Net Cash Flow ⓘ	0.01	-0	-0	-0	2.50	-2.33	29.85	-29.89	0	0

Finance Ratio

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Ratios
ROE (%)	-5.44	4.28	25.64	53.96	40.98	23.13	-4.41	-81.59	-4.03	-1.24
ROCE (%)	-3.5	3.28	21.78	32.32	22.41	15.11	0.45	-47.98	-1.89	-0.56
Asset Turnover Ratio	0.04	0.53	1.03	0.89	0.6	0.65	0.2	0.05	0	0
PAT to CFO Conversion(x)	N/A	5.8	0.9	-2.15	0.83	-0.94	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	61	10.20	6.90	58.70	89.20	96.70	263.40	444.30	2,559.70	0
Inventory Days	102.40	39.10	50	54.90	59.80	49.60	106.80	183.30	0	0
Payable Days	1,063.20	312.90	293.40	312.90	285.80	223.20	799.90	925.20	0	0

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

ABL Biotechnologies Ltd FAQs

The current trading price of ABL Biotechnologies on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of ABL Biotechnologies stood at ₹0.66 Cr

The latest P/E ratio of ABL Biotechnologies as of 31-Dec-1969 is 0.00.

The latest P/B ratio of ABL Biotechnologies as of 31-Dec-1969 is 0.05.

The 52-week high of ABL Biotechnologies is ₹0.81 and the 52-week low is ₹0.75.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of ABL Biotechnologies is ₹0.00 ( Cr.) .

About ABL Biotechnologies Ltd

ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates.

Companyâ€™s R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India.

Companyâ€™s microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms.

Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India.

Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states.

ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture.

Product portfolio

Company manufactures Beta carotene, which is used as a source of Vitamin A for protection against strokes and cataracts, enhancing the immune system, and preventing photo sensitivity disorders.ABL manufactures Lycopene, an antioxidant carotenoid and pigment that gives characteristic red colour to tomatoes, watermelon, and pink grapefruit.Company developed Lutein, a carotenoid found in fruits and vegetables, including dark green and leafy vegetables, such as spinach and kale, as well as in foods comprising corn and egg yolks.ABL Biotechnologies involves in the production of carotenoid fortified products, including jams, squashes, ketchups and sauces, cooking oils, and chocolates.

Future Plan

ABL Biotechnologies R&D unit plans to strengthen its product portfolio by developing new molecules.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

ABL Biotechnologies Ltd (526955) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating